=== "If the FDA’s action on the ATryn BLA is a full-fledged approval or a response that leaves only minor issues to be resolved, GTC can presumably engineer a buyout or merger transaction then at a substantial premium to the current share price." ===
Then..... it is obvious that this is GTCB shareholders' last gasp at getting a profitable return on investment. We need approval and then a substantial jump in share price prior to June 1st, in order to negate most of the LFB financing deal.
I think that the odds are good for an approval, seeing that ATryn has already been approved in EU, and that the EU data, combined with the US trials, are being used by the FDA AND that there has NEVER been any negative news regarding ATryn.
What are the chances for a substantial jump in share price after approval, and prior to June?
Market Data 
Markets 
AI
